Most viewed articles
Inside U.S. Trade reports that USTR has begun an “internal review of the controversial pharmaceutical patent proposal that U.S. trade officials tabled” earlier in the TPP negotiations. However, USTR has also signaled new text will not be ready by the next round of negotiations in Singapore in March. The initial U.S. proposal centered around an “access window,” granting TRIPS plus protection to firms that introduced their products within a certain period of time. It was opposed by all of the other negotiators, and the original text was withdrawn.
January 22, 2013
Source: Infojustice
- National traceability system for agro-forestry-fishery products to be launched on July 1
- European Parliament backs long-awaited digital euro to reduce US dominance in payments
- A decade after Brexit, Britain weighs costs and gains as it searches for a new leader
- Combating e-invoice fraud with big data technology
- Resolution 10-NQ/TW redefines foreign capital attraction